title: [Vascular effects of perindopril arginine and indapamide fixed combination in patients with arterial  hypertension].
abstract: The aim of the study was to investigate the dynamics of arterial stiffness and endothelial function parameters under the influence of perindopril arginine and indapamide fixed combination in arterial hypertension (AH) patients. 30 persons with 1-3 degree AH were included into the study. The treatment duration was 24 weeks. Central aortic blood pressure (BP), augmentation pressure and index (AIx), carotid-femoral and carotid-radial pulse wave velocity (PWV), brachial artery endothelium-dependent vasodilatation (EDVD), office and ambulatory BP as well as orthostatic BP falls were evaluated under the influence of selected therapy. 27 patients completed the study protocol. Results showed that aortic systolic BP was significantly reduced by 10.7 mmHg, augmentation pressure - by 3.6 mmHg and AIx - by 6.5%. Carotid-radial PWV decreased by 0.8 m/s. Carotid-femoral PWV did not change. We also revealed the EDVD increase by week 12. The EDVD growth was correlated with degree of aortic systolic BP reduction (r=-0.48, p=0.02). Office and ambulatory BP declined by 15.8/10.0 and 10.0/7.5 mmHg respectively. The target BP &lt;140/90 mmHg was achieved in 20 (74.1%) persons. At the same time the orthostatic hypotension did not rise. Conclusion. We concluded that perindopril arginine/indapamide fixed combination improved vascular function in hypertensive patients by wave reflection reduction, peripheral arterial stiffness lowering and endothelial function improvement.
authors.forename: K V
authors.initials: KV
authors.lastname: Protasov
authors.forename: D A
authors.initials: DA
authors.lastname: Sinkevich
authors.forename: I V
authors.initials: IV
authors.lastname: Reshina
authors.forename: N V
authors.initials: NV
authors.lastname: Zhizhko
authors.forename: S I
authors.initials: SI
authors.lastname: Logovikova
authors.forename: L V
authors.initials: LV
authors.lastname: Golubeva
mesh_terms: D000284:Administration, Oral; D000959:Antihypertensive Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics; D001158:Arteries / Q000187:drug effects / Q000503:physiopathology; D001682:Biological Availability; D001794:Blood Pressure / Q000187:drug effects*; D004338:Drug Combinations; D004357:Drug Synergism; D004730:Endothelium, Vascular / Q000187:drug effects / Q000503:physiopathology; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy / Q000503:physiopathology; D007190:Indapamide / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics; D008297:Male; D008875:Middle Aged; D020913:Perindopril / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics; D063177:Pulse Wave Analysis / Q000379:methods; D016896:Treatment Outcome; D014655:Vascular Resistance / Q000187:drug effects*; D014664:Vasodilation / Q000187:drug effects
chemical_list: D000959:Antihypertensive Agents; D004338:Drug Combinations; C494243:indapamide, perindopril drug combination; D007190:Indapamide; D020913:Perindopril